|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Recombinant Human CD147 / EMMPRIN / Basigin protein (Catalog#10186-H08H)|
|5 μl/Test, 0.1 mg/ml|
|Aqueous solution containing 0.5% BSA and 0.1% sodium azide|
|This antibody was obtained from a rabbit immunized with purified, recombinant Human WFDC2 / HE4 (rh WFDC2 / HE4; Catalog#12609-H08H; NP_006094.3; Met1-Phe124) and conjugated with PE under optimum conditions, the unreacted PE was removed.|
|Human CD147 / EMMPRIN / Basigin|
|This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze ! |
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
CD147/EMMPRIN (Extracellular Matrix Metalloproteinase Inducer), also known as Basigin (BSG), is a transmembrane glycoprotein with different forms resulted from different modes of glycosylation and N-terminal sequence variants. It is a member of the immunoglobulin superfamily with homology to both the immunoglobulin V domain and MHC class II antigen beta-chain. This protein play important roles in variety of events including spermatogenesis, embryo implantation, neural network formation. CD147 induces the production and release of matrix metalloproteinases (MMP) in the surrounding mesenchymal cells and tumor cells, and thereby promotes invasion, metastasis, growth and survival of malignant cells. Furthermore, CD147 also serves as a receptor for extracellular cyclophilinthe and its association with integrins might be important in signal transduction. Recently, CD147 displays increased expression in many cancers, and it has been previously demonstrated to participate in cancer metastasis and progression. Thus, CD147 and its antibody are used as an effective treatment for malignant cancers.